A Phase 4 interventional study of Interrupted apixaban and Uninterrupted apixaban in Atrial Fibrillation, sponsored by Baim Institute for Clinical Research. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-17.
Sponsored by Baim Institute for Clinical Research · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 993 studies in Atrial Fibrillation with a site in United States — 161 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.
Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 203rd largest by enrollment of the 679 interventional ones that give a count, is one of 28 that started in 2015, is one of 87 in phase 4, and was the 406th registered.
4,009 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →161 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:
Kardium Inc. · Sites in United States
Ages 18+
Boston Scientific Corporation · Sites in United States
Ages 18+
Bayer · Sites in United States, Belgium, Bulgaria and 5 more countries
Ages 18–85
Texas Cardiac Arrhythmia Research Foundation · Sites in United States
Ages 18+
Oslo University Hospital · Sites in United States, Belgium, France and 7 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
993 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 71 · Phase 3 107 · Phase 4 87
First in 1989; this study’s year is marked. 28 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 127 across the 679 interventional studies, 200 across the 308 observational. Of the 675 that completed or were terminated, 304 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
349 of 993 have an industry lead sponsor. The 10 most frequent:
Baim Institute for Clinical Research is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Baim Institute for Clinical Research has 2 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
76 of the studies in Atrial Fibrillation with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06376916Phase 3Wake Forest University Health SciencesComparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR | 2026-12 |
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02750319Phase 3Memorial Sloan Kettering Cancer CenterAmiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery | 2027-04 |
Add all 76 to your calendar (.ics) → With an account.
Among the 993 studies in Atrial Fibrillation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the prospective, randomized cohort in this study is to assess the safety and efficacy of 2 apixaban treatment strategies (uninterrupted versus interrupted) in subjects planned to undergo catheter ablation for the treatment of non-valvular atrial fibrillation (NVAF).
Simultaneously, a retrospective cohort of 300 warfarin-treated individuals, identified by chart review, who are matched to the prospective randomized subjects, will be identified. The purpose of the retrospective warfarin cohort is to compare the efficacy and safety of warfarin(the current clinical practice) to that of apixaban (uninterrupted, interrupted, combined uninterrupted and interrupted).
Prospective, Randomized Cohort
Subjects undergoing ablation for NVAF who meet all eligibility criteria and sign informed consent will be enrolled into the study. Subjects will be treated with apixaban for ≥21 days prior to the ablation procedure (for subjects already on apixaban for ≥21 days, it is not necessary to wait 21 days before the ablation procedure. Apixaban dose will be 5 mg b.i.d. per product label, or 2.5 mg b.i.d. in subjects with 2 or more of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.
Eligible subjects will then be randomized in a 1:1 ratio to 2 peri-procedural treatment strategies:
Randomization will take place prior to the procedure (on the day of the procedure or up to 3 days prior to the procedure) and will be stratified by site.
It is anticipated that up to 360 subjects may be enrolled in order to evaluate a total of 300 randomized subjects (150 subjects per treatment arm):
Randomized subjects will continue treatment with apixaban for 1 month post procedure.
Retrospective, Warfarin Cohort In addition, a chart review of 300 warfarin-treated patients who underwent catheter ablation for NVAF on or after September 1, 2013 in the enrolling centers and who have documented follow-up in the medical record for ≥ 30 days post-ablation procedure will be performed. Patient records for warfarin-treated individuals who meet the applicable inclusion/exclusion criteria and who are matched 1:1 to a subject in the prospective, randomized cohort for age (+/- 5 years), gender and atrial fibrillation (AF) type (paroxysmal vs. persistent), will be identified. Sites will document key demographic and outcome variables. This review will be performed in a blinded manner such that site personnel are blinded to the outcome of each retrospective subject during the subject selection process. Only pre-existing data will be collected for the analysis of this cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For women of (WOCBP):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
Drug: Interrupted apixaban
Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
Drug: Uninterrupted apixaban
Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
Also known as: Interrupted Eliquis
Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
Also known as: Uninterrupted Eliquis
Number of Patients With Clinically-Significant Bleeding
Clinically significant bleeding was defined as bleeding meeting Bleeding Academic Research Consortium (BARC) criteria type 2 or higher.
Time frame: Randomization to 1 month post catheter ablation
Number of Patients With Thrombotic Events
Thrombotic events were defined as a composite of non-hemorrhagic stroke and systemic thromboembolic events.
Time frame: Randomization to 1 month post catheter ablation
Number of Patients With Composite of Major Bleeding and Thrombotic Events
Major bleeding was defined as bleeding meeting BARC criteria type 3 or higher. Thrombotic events were defined as a composite of non-hemorrhagic stroke and systemic thromboembolic events.
Time frame: Randomization to 1 month post catheter ablation
Number of Patients With Composite of Clinically Significant Bleeding and Thrombotic Events
Thrombotic events were defined as a composite of non-hemorrhagic stroke and systemic thromboembolic events. Clinically significant bleeding was defined as bleeding meeting Bleeding Academic Research Consortium (BARC) criteria type 2 or higher.
Time frame: Randomization to 1 month post catheter ablation
Number of Patients With Clinically-Significant Bleeding
Clinically significant bleeding was defined as bleeding meeting Bleeding Academic Research Consortium (BARC) criteria type 2 or higher.
Time frame: Enrollment to 1 month post catheter ablation
Number of Patients With Major Bleeding
Major bleeding was defined as bleeding meeting BARC criteria type 3 or higher.
Time frame: Randomization to 1 month post catheter ablation
Number of Patients With Major Bleeding
Major bleeding was defined as bleeding meeting BARC criteria type 3 or higher.
Time frame: Enrollment to 1 month post catheter ablation
Number of Patients With Thrombotic Events
Thrombotic events were defined as a composite of non-hemorrhagic stroke and systemic thromboembolic events.
Time frame: Enrollment to 1 month post catheter ablation
Number of Patients With Composite of Clinically Significant Bleeding and Thrombotic Events
Thrombotic events were defined as a composite of non-hemorrhagic stroke and systemic thromboembolic events. Clinically significant bleeding was defined as bleeding meeting Bleeding Academic Research Consortium (BARC) criteria type 2 or higher.
Time frame: Enrollment to 1 month post catheter ablation
Number of Patients With Composite of Major Bleeding and Thrombotic Events
Thrombotic events are defined as a composite of non-hemorrhagic stroke and systemic thromboembolic events. Major bleeding is defined as bleeding meeting BARC criteria type 3 or higher.
Time frame: Enrollment to 1 month post catheter ablation
Number of Patients With TIAs or Non-Hemorrhagic Strokes
Number of Patients who had TIAs or non-hemorrhagic strokes.
Time frame: Enrollment to 1 month post catheter ablation
Number of Patients With TIAs or Non-Hemorrhagic Strokes
This measurement includes TIAs or non-hemorrhagic strokes.
Time frame: Randomization to 1 month post catheter ablation
Number of Patients With Death
Death is included in this measurement.
Time frame: Enrollment to 1 month post catheter ablation
Number of Patients With Cardiovascular Death
Cardiovascular death is included in this measurement.
Time frame: Enrollment to 1 month post catheter ablation
Number of Patients With Death
Death is included in this measurement.
Time frame: Randomization to 1 month post catheter ablation
Number of Patients With Cardiovascular Death
Cardiovascular death is included in this measurement.
Time frame: Randomization to 1 month post catheter ablation
| Milestone | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Started | 148 | 152 |
| Safety | 149 | 151 |
| Completed | 145 | 150 |
| Not completed | 3 | 2 |
| Withdrew: Ablation procedure not initiated | 3 | 2 |
Clinically significant bleeding was defined as bleeding meeting Bleeding Academic Research Consortium (BARC) criteria type 2 or higher.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Clinically-Significant Bleeding | 14 | 17 |
Thrombotic events were defined as a composite of non-hemorrhagic stroke and systemic thromboembolic events.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Thrombotic Events | 0 | 0 |
Major bleeding was defined as bleeding meeting BARC criteria type 3 or higher. Thrombotic events were defined as a composite of non-hemorrhagic stroke and systemic thromboembolic events.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Composite of Major Bleeding and Thrombotic Events | 3 | 2 |
Thrombotic events were defined as a composite of non-hemorrhagic stroke and systemic thromboembolic events. Clinically significant bleeding was defined as bleeding meeting Bleeding Academic Research Consortium (BARC) criteria type 2 or higher.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Composite of Clinically Significant Bleeding and Thrombotic Events | 14 | 17 |
Clinically significant bleeding was defined as bleeding meeting Bleeding Academic Research Consortium (BARC) criteria type 2 or higher.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Clinically-Significant Bleeding | 17 | 17 |
Major bleeding was defined as bleeding meeting BARC criteria type 3 or higher.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Major Bleeding | 3 | 2 |
Major bleeding was defined as bleeding meeting BARC criteria type 3 or higher.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Major Bleeding | 3 | 2 |
Thrombotic events were defined as a composite of non-hemorrhagic stroke and systemic thromboembolic events.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Thrombotic Events | 0 | 0 |
Thrombotic events were defined as a composite of non-hemorrhagic stroke and systemic thromboembolic events. Clinically significant bleeding was defined as bleeding meeting Bleeding Academic Research Consortium (BARC) criteria type 2 or higher.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Composite of Clinically Significant Bleeding and Thrombotic Events | 14 | 17 |
Thrombotic events are defined as a composite of non-hemorrhagic stroke and systemic thromboembolic events. Major bleeding is defined as bleeding meeting BARC criteria type 3 or higher.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Composite of Major Bleeding and Thrombotic Events | 3 | 2 |
Number of Patients who had TIAs or non-hemorrhagic strokes.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With TIAs or Non-Hemorrhagic Strokes | 1 | 1 |
This measurement includes TIAs or non-hemorrhagic strokes.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With TIAs or Non-Hemorrhagic Strokes | 1 | 1 |
Death is included in this measurement.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Death | 0 | 0 |
Cardiovascular death is included in this measurement.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Cardiovascular Death | 0 | 0 |
Death is included in this measurement.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Death | 0 | 0 |
Cardiovascular death is included in this measurement.
| Participants | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Number of Patients With Cardiovascular Death | 0 | 0 |
Collected over 1 Month. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Interrupted Apixaban | 0/149 (0%) | 14/149 (9.4%) | 72/149 (48.3%) |
| Uninterrupted Apixaban | 0/151 (0%) | 15/151 (9.9%) | 75/151 (49.7%) |
| Event | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Atrial FibrillationCardiac disorders | 2/149 | 3/151 |
| Arrhythmia SupraventricularCardiac disorders | 2/149 | 1/151 |
| Atrial FlutterCardiac disorders | 2/149 | 1/151 |
| HypotensionVascular disorders | 0/149 | 2/151 |
| Urinary Tract InfectionInfections and infestations | 0/149 | 2/151 |
| Catheter Site HaemorrhageGeneral disorders | 1/149 | 0/151 |
| Pneumonia MycoplasmalInfections and infestations | 1/149 | 0/151 |
| Vascular PseudoaneurysmInjury, poisoning and procedural complications | 1/149 | 1/151 |
| Fluid OverloadMetabolism and nutrition disorders | 1/149 | 0/151 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/149 | 0/151 |
| Event | Interrupted Apixaban | Uninterrupted Apixaban |
|---|---|---|
| Atrial fibrillationCardiac disorders | 13/149 | 7/151 |
| Arrhythmia supraventricularCardiac disorders | 10/149 | 9/151 |
| Catheter site haemorrhageGeneral disorders | 8/149 | 5/151 |
| Atrial flutterCardiac disorders | 7/149 | 3/151 |
| NauseaGastrointestinal disorders | 7/149 | 7/151 |
| Catheter site painGeneral disorders | 7/149 | 3/151 |
| Non-cardiac chest painGeneral disorders | 6/149 | 6/151 |
| Catheter site haematomaGeneral disorders | 5/149 | 2/151 |
| Back painMusculoskeletal and connective tissue disorders | 5/149 | 0/151 |
| Oedema peripheralGeneral disorders | 2/149 | 5/151 |
| Age, Continuous(Years) | Interrupted Apixaban | Uninterrupted Apixaban | Total |
|---|---|---|---|
| Mean | 64.3 ± 10.3 | 62.8 ± 9.9 | 63.5 ± 10.1 |
| Sex: Female, Male(Participants) | Interrupted Apixaban | Uninterrupted Apixaban | Total |
|---|---|---|---|
| Female | 48 | 49 | 97 |
| Male | 97 | 101 | 198 |
| Ethnicity (NIH/OMB)(Participants) | Interrupted Apixaban | Uninterrupted Apixaban | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 134 | 143 | 277 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Interrupted Apixaban | Uninterrupted Apixaban | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 133 | 141 | 274 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body Mass Index(kg/m2) | Interrupted Apixaban | Uninterrupted Apixaban | Total |
|---|---|---|---|
| Mean | 30.46 ± 5.607 | 30.58 ± 6.441 | 30.52 ± 6.036 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Nov 2015, a primary completion of Apr 2017 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2020, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Baim Institute for Clinical Research